Perspective Therapeutics (NYSE:CATX) Trading Up 4.9% – Should You Buy?

Perspective Therapeutics, Inc. (NYSE:CATX)’s stock price traded up 4.9% on Tuesday . The stock traded as high as $12.89 and last traded at $12.89. 269,258 shares traded hands during mid-day trading, a decline of 61% from the average session volume of 683,831 shares. The stock had previously closed at $12.29.

Analysts Set New Price Targets

A number of research analysts have recently commented on CATX shares. Oppenheimer reissued an “outperform” rating and set a $22.00 price target on shares of Perspective Therapeutics in a report on Friday. Bank of America initiated coverage on shares of Perspective Therapeutics in a research report on Thursday, July 25th. They set a “buy” rating and a $24.00 price target on the stock. Wedbush started coverage on shares of Perspective Therapeutics in a report on Tuesday, October 1st. They issued an “outperform” rating and a $25.00 price objective for the company. Royal Bank of Canada dropped their price target on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a report on Friday, August 16th. Finally, Truist Financial initiated coverage on Perspective Therapeutics in a research note on Wednesday, September 25th. They set a “buy” rating and a $21.00 price objective for the company. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Perspective Therapeutics has a consensus rating of “Buy” and an average target price of $21.43.

Perspective Therapeutics Stock Performance

The stock’s 50 day simple moving average is $13.83.

Perspective Therapeutics (NYSE:CATX) last released its earnings results on Monday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.04. The business had revenue of $0.53 million during the quarter. Equities research analysts expect that Perspective Therapeutics, Inc. will post -0.87 EPS for the current year.

Institutional Trading of Perspective Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Bleakley Financial Group LLC bought a new stake in Perspective Therapeutics in the first quarter valued at about $40,000. Victory Capital Management Inc. acquired a new stake in Perspective Therapeutics during the second quarter valued at approximately $117,000. Point72 DIFC Ltd bought a new stake in shares of Perspective Therapeutics in the 2nd quarter valued at approximately $118,000. RIA Advisory Group LLC raised its holdings in shares of Perspective Therapeutics by 1,313.4% in the 1st quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock worth $127,000 after buying an additional 99,293 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Perspective Therapeutics during the 1st quarter worth approximately $138,000. 54.66% of the stock is currently owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.